No Data
No Data
Unusual Options Activity: KMB, BA and Others Attract Market Bets, KMB V/OI Ratio Reaches 183.3
Cystic Fibrosis Market Is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech, Aridis Pharmaceuticals, BiomX, Inc., Boehringer Ingelheim
Stifel Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $204
Stifel Nicolaus Remains a Buy on Krystal Biotech (KRYS)
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,200 Today
How Is The Market Feeling About Krystal Biotech?
No Data